Neurophysiological effects of a combined treatment of lovastatin and minocycline in patients with fragile X syndrome: Ancillary results of the LOVAMIX randomized clinical trial.
A daily mix of lovastatin and minocycline calmed brain excitability in adults with fragile X, and a simple TMS thumb-twitch test can track the change.
01Research in Context
What this study did
Florence et al. (2024) ran a 20-week drug trial with adults who have fragile X.
Half took both lovastatin and minocycline every day. The rest took only one of the pills.
The team used TMS pulses to check how easily each brain fired before and after treatment.
What they found
The combo group needed stronger pulses to make thumb muscles twitch. That means their cortex was calmer.
The single-drug groups only showed a small hint of better GABA quieting.
How this fits with other research
Hall et al. (2020) and Foti et al. (2015) cut problem behavior by 90% with telehealth FCT in boys. Florence shows a pill may also calm the brain, but in adults and measured with a magnet, not a tantrum count.
Hsing-Liu et al. (2025) tried daily theta-burst TMS in autistic youth and saw no clinical gain, yet Florence used TMS only as a yardstick and still found a drug signal. The difference is purpose: one treated, the other simply read the brain.
Gwynette et al. (2020) gave therapeutic rTMS to depressed autistic adults and mood lifted. Florence did not stimulate; they dosed pills and watched quieter motor thresholds appear. Same tool, opposite direction.
Why it matters
You now have a quick, non-invasive marker—resting motor threshold—to see if a fragile X drug is working. No spinal taps, no long wait for behavior change. Track the number every month. If it rises, the cortex is cooling and the pills may be helping. If it stays flat, think dose tweak or switch.
Want CEUs on This Topic?
The ABA Clubhouse has 60+ free CEUs — live every Wednesday. Ethics, supervision & clinical topics.
Join Free →Ask the prescribing doctor for recent resting motor-threshold scores and plot them on a trend line in the client’s file.
02At a glance
03Original abstract
Fragile X syndrome (FXS) is the primary hereditary cause of intellectual disability and autism spectrum disorder. It is characterized by exacerbated neuronal excitability, and its correction is considered an objective measure of treatment response in animal models, a marker albeit rarely used in clinical trials. Here, we used an extensive transcranial magnetic stimulation (TMS) battery to assess the neurophysiological effects of a therapy combining two disease-modifying drugs, lovastatin (40 mg) and minocycline (100 mg), administered alone for 8 weeks and in combination for 12 weeks, in 19 patients (mean age of 23.58 ± 1.51) with FXS taking part in the LOVAmix trial. The TMS battery, which included the resting motor threshold, short-interval intracortical inhibition, long-interval intracortical inhibition, corticospinal silent period, and intracortical facilitation, was completed at baseline after 8 weeks of monotherapy (visit 2 of the clinical trial) and after 12 weeks of dual therapy (visit 4 of the clinical trial). Repeated measure ANOVAs were performed between baseline and visit 2 (monotherapy) and visit 3 (dual therapy) with interactions for which monotherapy the participants received when they began the clinical trial. Results showed that dual therapy was associated with reduced cortical excitability after 20 weeks. This was reflected by a significant increase in the resting-motor threshold after dual therapy compared to baseline. There was a tendency for enhanced short-intracortical inhibition, a marker of GABAa-mediated inhibition after 8 weeks of monotherapy compared to baseline. Together, these results suggest that a combined therapy of minocycline and lovastatin might act on the core neurophysiopathology of FXS. This trial was registered at clinicaltrials.gov (NCT02680379).
Autism research : official journal of the International Society for Autism Research, 2024 · doi:10.1002/aur.3222